Maypharm website sells unapproved, misbranded Botulax botulinum toxin to U.S. consumers, FDA says.
What happened
FDA reviewed www.maypharm.net and found it offering injectable botulinum toxin type A marketed as “BOTULAX 200 units” and “Botulax 200ui” for uses such as hyperhidrosis, blepharospasm, and deep wrinkles. FDA says the product is an unapproved new drug because no FDA-approved application is in effect, and it is misbranded because its labeling lacks adequate directions for use. No inspection was reported.
What FDA found
Maypharm offered Botulax botulinum toxin for sale in the U.S. without an FDA-approved drug application.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The Botulax labeling did not include adequate directions for safe use by a layperson, so the drug is misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]By offering the drug to U.S. consumers, the website caused misbranded drugs to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Maypharm to stop offering unapproved and misbranded drugs to U.S. consumers, review its websites and labeling, and respond in writing within 15 working days with the steps taken and documentation. If it cannot complete corrections in that time, it must explain the delay and give a completion date.
Who should pay attention
- U.S. clinics and med spas that buy injectables online
- online sellers and importers of botulinum toxin products
- consumers considering injectable treatments from foreign websites
This is a summary. Read the original letter on fda.gov.